Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.34 which represents a slight increase of $1.75 or 1.93% from the prior close of $90.59. The stock opened at $91.35 and ...

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

For years, Gilead Sciences was dead money for shareholders. That is starting to change, and a recent rally in the stock can ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.13 which represents a decrease of $-1.26 or -1.35% from the prior close of $93.39. The stock opened at $93.5 and touched a low ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...